
CIBC International Equity Index ETF Trust Units (TSE:CIEI) Price & Chart
TSE:CIEI ETF Chart & Stats
- Day’s Range
- CAD 31.85 - CAD 32.06
- 52-Week Range
- CAD 27.87 - CAD 33.64
- Previous Close
- CAD 31.10
- Volume
- 1,470
- Average Volume (3M)
- 12.99K
- AUM
- 593.28M
- NAV
- 31.04
- Expense Ratio
- 0.78%
- Holdings Count
- 657
- Beta
- 0.86
- Inception Date
- Mar 31, 2021
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 18,775,000
- Standard Deviation
- N/A
ETF Overview
CIBC International Equity Index ETF Trust Units
The CIBC International Equity Index ETF Trust Units, trading under the ticker TSE:CIEI, is a compelling choice for investors seeking broad-based exposure to the global equity landscape. This ETF is meticulously designed to mimic the performance of a diverse array of international stocks, capturing the essence of a total market approach. By focusing on a size and style category that embraces the entire spectrum of the market, it provides a comprehensive investment solution that spans various regions and sectors. As a part of its broad-based niche, CIEI aims to offer investors a seamless way to tap into international markets, thus providing an effective diversification strategy beyond domestic borders. This broad scope is particularly advantageous for those looking to mitigate risk while capitalizing on global growth opportunities. The fund's structure allows investors to gain access to a multitude of companies, from burgeoning enterprises to well-established giants, across a multitude of industries. CIBC International Equity Index ETF Trust Units stands out for its commitment to replicating the performance of international equities, making it an ideal vehicle for those looking to enhance their portfolio with global reach and diversity. Whether you are an individual investor seeking international exposure or a portfolio manager aiming to balance regional allocations, TSE:CIEI offers a strategically diversified solution that aligns with the dynamic nature of global markets.
- Asset Class
- Equity
- Region
- Developed Markets
- Issuer
- CIBC
- Index Tracked
- MSCI EAFE Index - CAD
- Ticker Symbol
- TSE:CIEI
TSE:CIEI ETF News


AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s TREVI-OC-02 study is testing torvutatug samrotecan with bevacizumab as first-line maintenance treatment for advanced ovarian, fallopian

AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s Phase 3 MATTERHORN-CN study is testing treatment for Chinese patients with operable gastric and gastroesophageal junction










